Pubblicazioni

Autori:

Salzano, Serena; Caltabiano, Rosario; Magro, Gaetano; D'Amati, Antonio; Pizzimenti, Cristina; Maugeri, Andrea; Agodi, Antonella; Barbagallo, Giuseppe; Certo, Francesco; Fiorentino, Francesco; Tuccari, Giovanni; Martini, Maurizio; Ieni, Antonio; Barresi, Valeria; Broggi, Giuseppe

Titolo:

MTAP and p16 as immunohistochemical surrogates of CDKN2A/B homozygous deletion in central nervous system tumors: A multicentre Italian experience

Anno:

2025

Tipologia prodotto:

Articolo in Rivista

Tipologia ANVUR:

Articolo su rivista

Lingua:

Inglese

Formato:

Elettronico

Referee:

No

Nome rivista:

ANNALS OF DIAGNOSTIC PATHOLOGY

ISSN Rivista:

1092-9134

N° Volume:

79

Intervallo pagine:

1-6

Parole chiave:

CDKN2A/B homozygous deletion; Central nervous system tumors; MTAP; p16

Breve descrizione dei contenuti:

Objective: To evaluate the diagnostic performance of MTAP and p16 immunohistochemistry (IHC) as surrogate markers for CDKN2A/B homozygous deletion (HD) in central nervous system (CNS) tumors, and to assess their prognostic significance. Methods: Molecular tests including gene sequencing or fluorescence in situ hybridization (FISH) have traditionally been used to assess CDKN2A/B HD. However, due to lower costs and wider availability, IHC surrogates such as MTAP and p16 are gaining interest. We investigated the concordance between MTAP and p16 IHC expression and CDKN2A/B status as determined by FISH. Results: Our cohort consisted of 227 patients with various CNS tumor types: glioblastoma IDH-wild type (n = 64; 28.2 %), meningioma (n = 61; 26.9 %), IDH-mutant astrocytoma (n = 52; 22.9 %), IDH-mutant and 1p/19q-codeleted oligodendroglioma (n = 35; 15.4 %), and pleomorphic xanthoastrocytoma (n = 15; 6.6 %). In all tumor types, most cases with CDKN2A/B HD showed MTAP loss and p16 negativity (p-values < 0.05). The combination of MTAP and p16 IHC yielded a sensitivity of 92 %, specificity of 80 %, positive predictive value of 86 %, and negative predictive value of 88 % in detecting CDKN2A/B HD. Survival analysis demonstrated significantly reduced disease-free and overall survival among patients with MTAP loss, p16 negativity, and CDKN2A/B HD. Conclusions: MTAP immunohistochemistry, alone or combined with p16, represents a cost-effective and feasible surrogate for detecting CDKN2A/B homozygous deletion in CNS tumors and provides relevant prognostic information.

Note:

Available online 7 July 2025, Version of Record 9 July 202

Id prodotto:

146679

Handle IRIS:

11562/1166731

ultima modifica:

18 luglio 2025

Citazione bibliografica:

Salzano, Serena; Caltabiano, Rosario; Magro, Gaetano; D'Amati, Antonio; Pizzimenti, Cristina; Maugeri, Andrea; Agodi, Antonella; Barbagallo, Giuseppe; Certo, Francesco; Fiorentino, Francesco; Tuccari, Giovanni; Martini, Maurizio; Ieni, Antonio; Barresi, Valeria; Broggi, Giuseppe, MTAP and p16 as immunohistochemical surrogates of CDKN2A/B homozygous deletion in central nervous system tumors: A multicentre Italian experience «ANNALS OF DIAGNOSTIC PATHOLOGY» , vol. 79 , 2025 , pp. 1-6

Consulta la scheda completa presente nel repository istituzionale della Ricerca di Ateneo